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Abstract
Background: Treacher Collins syndrome (TCS) is an autosomal dominant craniofacial disorder caused
by frameshift deletions or duplications in the TCOF1 gene. These mutations cause premature termination
codons, which are predicted to lead to mRNA degradation by nonsense mediated mRNA decay (NMD).
Haploinsufficiency of the gene product (treacle) during embryonic development is the proposed molecular
mechanism underlying TCS. However, it is still unknown if TCOF1 expression levels are decreased in post-
embryonic human cells.
Methods: We have estimated TCOF1 transcript levels through real time PCR in mRNA obtained from
leucocytes and mesenchymal cells of TCS patients (n = 23) and controls (n = 18). Mutational screening and
analysis of NMD were performed by direct sequencing of gDNA and cDNA, respectively.
Results: All the 23 patients had typical clinical features of the syndrome and pathogenic mutations were
detected in 19 of them. We demonstrated that the expression level of TCOF1 is 18-31% lower in patients
than in controls (p < 0.05), even if we exclude the patients in whom we did not detect the pathogenic
mutation. We also observed that the mutant allele is usually less abundant than the wild type one in
mesenchymal cells.
Conclusions: This is the first study to report decreased expression levels of TCOF1 in TCS adult human
cells, but it is still unknown if this finding is associated to any phenotype in adulthood. In addition, as we
demonstrated that alleles harboring the pathogenic mutations have lower expression, we herein
corroborate the current hypothesis of NMD of the mutant transcript as the explanation for diminished
levels of TCOF1 expression. Further, considering that TCOF1 deficiency in adult cells could be associated
to pathologic clinical findings, it will be important to verify if TCS patients have an impairment in adult stem
cell properties, as this can reduce the efficiency of plastic surgery results during rehabilitation of these
patients.
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Background
Treacher Collins syndrome (TCS; OMIM 154500) is a rare
autosomal dominant craniofacial disorder (1:50.000)
characterized by bilateral and symmetrical malforma-
tions, which frequently includes hypoplasia of the mandi-
ble and zygomatic complex, down-slanting palpebral
fissures, coloboma of the lower eyelid and absence of eye-
lashes medial to this defect, external and middle ear mal-
formation, and conductive hearing loss [1]. The
penetrance is considered to be complete, but there is a
high inter and intra-familial phenotypic variation, rang-
ing from cases with perinatal death due to airway obstruc-
tion by severe orofacial malformations to those that are
not clinically diagnosed [2].
In most of the cases the disorder is caused by frameshift
deletions or duplications of 1-41 bp in TCOF1 coding
region which cause premature termination codons (PTC).
Except for a recurring 5 bp deletion in exon 24 that is
responsible for 17% of the cases, mutations are usually
family-specific [3]. TCOF1  gene product is a nucleolar
protein (treacle) involved in rRNA transcription and in
pre-rRNA post-transcriptional modification [4]. Trun-
cated proteins are not detected in TCS patients' fibroblasts
and lymphocytes, suggesting that mRNA bearing PTCs are
being degraded by nonsense mediated mRNA decay
(NMD) [5]; however, NMD has never been demonstrated
in human or mouse cells with null mutations in TCOF1.
No genotype-phenotype correlation has been observed in
TCS and there is also no evidence of association between
the disease severity and parental origin or type of the path-
ogenic mutation, male or female sex, sporadic or familial
cases [5-9].
TCOF1 is expressed in various adult and embryonic tis-
sues and haploinsufficiency of treacle during embryonic
development has been proposed as the molecular mecha-
nism underlying TCS [10]. In situ hybridization studies of
the Tcof1 orthologue demonstrated that there is a peak of
expression of the gene in E8.5-9.5 mice embryos, espe-
cially in the first and second pharyngeal arches [11]. Crit-
ical dosage of Tcof1  for appropriate craniofacial
development has been further demonstrated in Tcof1+/-
mice [12,13]. Interestingly, a previous study observed that
cellular amount of treacle in fibroblasts and lymphocytes
derived from TCS patients was indistinguishable from
that of control individuals, and the authors suggested that
a dosage compensation mechanism could occur in adult-
hood to compensate the null allele [5]. However, until the
present, these findings have not been confirmed.
The relevance of TCOF1 happloinsufficiency during adult
life is still rarely studied: it can predispose to age related
macular degeneration [14] and explain the absence of
long-term stable results in mandibular distraction for
facial reconstruction [15-17]. These findings might imply
that TCOF1 adult stem cells present a decreased regenera-
tive capacity in comparison to wild-type cells. We have
therefore conducted the present study to verify if TCOF1
expression is altered in adult TCS cells as well as to iden-
tify a source of human tissue suitable for functional stud-
ies of treacle in adulthood.
Methods
Patients and controls
We studied peripheral blood samples from 20 TCS
patients (TCS1 to 20, ranging from 3 to 41 years old)
referred to our center for genetic counseling and 12 con-
trols (ranging from 20 to 50 years old). We also obtained
tissue samples from TCS16, from three other patients
(TCS21 to 23), and from six controls submitted to recon-
structive plastic surgery at University of São Paulo Medical
School. The study was approved by the ethical committee
of our Institution and informed consent was obtained
from both patients and control subjects or from their legal
tutors. In total, 23 TCS patients were studied.
Isolation of cells from periosteum of TCS patients
During corrective surgery, overlying periosteum from the
face of four TCS patients (two males and two females aged
from 6 to 29 years) was meticulously dissected away from
surrounding tissues to isolate intact periosteal flaps. Con-
trol periosteum was obtained using the same procedure
from facial region of six subjects (four males and two
females aged from 11 months to 20 years) with no evi-
dence of bone disease during corrective surgery.
Mesenchymal cells were isolated as described by previous
reports from our group [18,19]. The periosteal flaps were
thoroughly washed with sterile phosphate-buffered saline
(PBS) supplemented with 4% antibiotics (100 units/mL
penicillin and 100 mg/mL streptomycin; Invitrogen), and
digested with trypsin solution (TrypLe; Invitrogen) for 1 h
at 37°C. Once digested, the tissue was transferred with
minimal dissection into 35 mm Petri dishes (Corning,
NY) containing Dulbecco's modified Eagle's medium
(DMEM; GIBCO) with 10% fetal bovine serum (FBS;
GIBCO), 100 units/mL penicillin, and 100 mg/mL strep-
tomycin (Invitrogen). After two weeks, cells were washed
with PBS, then dissociated in trypsin solution and seeded
at 104 cells per 25 cm2 for the first passage. For expansion,
cells were cultured in monolayer in growth medium at
37°C in a humidified atmosphere of 5% CO2. The
medium was replaced every 3 days. In order to prevent cell
differentiation, cultures were maintained semiconfiuent
and subcultured every 4-5 days with daily medium
changes.
Flow cytometry
Cells were harvested with TrypLe (Invitrogen), washed
with PBS, and incubated at 4°C for 30 min with the fol-BMC Medical Genetics 2009, 10:136 http://www.biomedcentral.com/1471-2350/10/136
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lowing anti-human antibodies: CD29-PE CY5, CD90
(Thy-1), CD45-FITC, CD73, CD105, CD117, CD 31-PE
(Becton Dickinson) and SH3 (Case Western Reserve Uni-
versity). After the wash, unconjugated primary antibodies
were incubated with anti-mouse-PE secondary antibody
(Guava Technologies) for additional 15 min at 4°C.
Finally, the cell suspension was washed with PBS, and 104
labeled cells were acquired with an EasyCyte flow cytom-
eter (Guava Technologies). Control samples were incu-
bated with PBS instead of primary antibody, followed by
incubation with anti-mouse-PE secondary antibody. All
the generated plots were analyzed in Guava ExpressPlus
software (Guava Technologies).
DNA and RNA isolation and cDNA synthesis
Genomic DNA from peripheral blood samples was
obtained according to reference [20] and genomic DNA
from culture cells was extracted using NucleoSpin Tissue
extraction kits (Macherey-Nagel). Total RNA was isolated
from leucocytes and mesenchymal cells using TRIzol®
(Gibco BRL), treated with DNAse (Promega) and submitted
to reverse transcription using Superscript II Reverse Tran-
scriptase (Gibco BRL), according to manufacturer's proto-
col. Aliquots from DNAse  treated RNAs were used for
amplification of an intronic region of MLH1 gene as a
control for DNA contamination (primers sequences on
request).
Mutation screening
Seven of the 23 patients included in the present report
were previously studied by our group [3,9,21]. Pathogenic
mutations were identified in six of these seven individuals
(Table 1). Except for patient TCS17, for whom we did not
have enough DNA, all the other 15 patients were submit-
ted to molecular analysis to identify the pathogenic muta-
tion. Screening of TCOF1 mutations by direct sequencing
of genomic DNA was performed with primers described
elsewhere [9]. Sequencing of the patients' cDNA was per-
formed in identical conditions, but using primers that
amplify only the coding region flanking the pathogenic
mutation (see Additional file 1).
Real Time PCR
Real time quantitative PCR reactions were performed in
duplicates with a final volume of 20 μl, using 12.5 ng of
cDNA, 1× SYBR Green PCR Master Mix (Applied Biosystems)
and 200 or 400 nM of each primer. We used ABI Prism
7700 Sequence Detection System (Applied Biosystems) with
standard temperature protocol. Primers were designed
with Primer Express software V.2.0 (Applied Biosystems;
primers sequence in Additional file 1) and the amplifica-
tion efficiency (E) of each primer was calculated according
to the equation E = 10(-1/slope). The expression data of
TCOF1 transcripts was determined by relative quantifica-
tion in comparison to a pool of RNA from 10 controls.
Four endogenous controls genes (GAPDH, BCRP, HPRT1,
and  HMBS), were used and their stability was verified
through geNorm VBA applet designed for Microsoft Excel.
This tool calculates the most stable reference genes from a
set of tested candidate reference genes in a given sample
panel, and calculates the gene expression normalization
factor (NF) for each target sample based on the geometric
mean of a user-defined number of housekeeping genes
[22]. We calculated the NF for each sample based on the
four endogenous controls and the expression data was cal-
culated according to reference [23].
Results
Molecular characterization of the TCS patients
Pathogenic mutations were identified in 13 of the novel
15 screened individuals: five had already been reported as
pathogenic [9,21,24] and eight are herein described for
the first time. These new mutations were considered path-
ogenic because they are a nonsense mutation
(c.1609C>T), disrupt splicing (c.639+1G>A) or alter the
reading frame (c.3853delC, c.1298delC,
c.218_222insAACC, c.4344dupA, c.431delC). Mutation
c.4375_4377delAAG (TCS18) causes an in phase deletion
and excludes a Lysine residue from the protein C-terminal
nucleolar localization signal [25]. In Table 1, mutation
and tissue availability of each patient are depicted.
RT-PCR in leucocytes
We first verified the range of TCOF1 transcript levels in
leucocytes from 20 patients (Table 1) and 12 controls by
real-time PCR, using as reference a pool of RNA from 10
controls. We observed a wide variation in TCOF1 expres-
sion in leucocytes from normal individuals (Figure 1; SD
= 1.24). This wide variation of gene expression was also
observed among TCS patients (Table 1; SD = 1.46), and
was not correlated to age (p = 0.39; Two-tailed Pearson
correlation regression).
Comparing patients (mean ± SEM = 6.846 ± 0.3278; N =
20) and controls (mean ± SEM = 8.093 ± 0.3587; N = 12),
we observed that TCOF1 expression levels were signifi-
cantly lower in patients than in controls (p = 0.0164; Two-
tailed unpaired t test with Welch's correction; Figure 1),
and the variances were not significantly different between
these two groups (p = 0.5828, F test). TCS patients had
approximately 18% less TCOF1 transcript levels than nor-
mal individuals. Excluding the four patients without an
identified pathogenic mutation, we obtained similar
results (~18.5%, p = 0.0039).
RT-PCR in mesenchymal cells
We also examined whether TCOF1 expression levels were
decreased in mesenchymal cells. Flow cytometry results
showed that most of the cells were positive for mesenchy-
mal cell markers (>95%) and negative for endothelial andBMC Medical Genetics 2009, 10:136 http://www.biomedcentral.com/1471-2350/10/136
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Table 1: Pathogenic mutations of TCS patients analyzed for TCOF1 expression:









Screened in the present 
study?
Reference
TCS1 (intron 6) c.639+1G>A g.11932G>A disrupted splicing Yes New
TCS2 (exon 23) c.4061delC g.38890delC p.Pro1354fs No [21]
TCS3 (exon 10) c.1609C>T g.17788C>T p.Gln537X Yes New
TCS4 (exon 14)c.2478G>A g.21371G>A disrupted splicing No [6,9]
TCS5 (exon 23) c.3853delC g.38682delC p.Gln1285fs Yes New
TCS6 (exon 18) c.3053_3054delGA g.32222_32223delGA p.Arg1018fs No [9]
TCS7 (exon 18) c.3053_3054delGA g.32222_32223delGA p.Arg1018fs No [9]
TCS8 (exon 24) 
c.4366_4370delGAAAA
g.40706_40710delGAAAA p.Lys1457fs No [7,9,21]
TCS9 Not detected - - No [3]
TCS10 (exon 8) c.1095_1096delAG g.16957_16958delAG p.Gly366fs Yes [24]
TCS11 (exon 8) c.1095_1096delAG g.16957_16958delAG p.Gly366fs Yes [24]
TCS12 (exon 24) 
c.4361_4365delAAAAA
g.40701_40705delAAAAA p.Lys1454fs No [7,21]
TCS13 (exon 9) c.1298delC g.17302delC p.Ala433fs Yes New
TCS14 Not detected - - Yes -
TCS15 Not detected - - Yes -
TCS16 (exon 3) c.218_222insAACC g.6495_6499insAACC p.Ala73fs Yes New
TCS17 Not screened - - - -
TCS18 (exon 24) 
c.4375_4377delAAG
g.40715_40715delAAG p.Lys1459del Yes New
TCS19 (exon 12) 
c.2103_2106delTGAG
g.18620_18623delTGAG p.Ser701fs Yes [21]
TCS20 (exon 12) 
c.2103_2106delTGAG
g.18620_18623delTGAG p.Ser701fs Yes [21]
DNA and RNA from mesenchymal cells
TCS16 (exon 3) c.218_222insAACC g.6495_6499insAACC p.Ala73fs - -
TCS21 (exon 24) c.4344dupA g.40684dupA p.Arg1448fs Yes New
TCS22 (exon 5) c.431delC g.11097delC p.Thr144fs Yes New
TCS23 (exon 23) c.4218dupG g.39047dupG p.Ser1407fs Yes [9]BMC Medical Genetics 2009, 10:136 http://www.biomedcentral.com/1471-2350/10/136
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hematopoietic markers (see Additional files 2 and 3) in
primary cell cultures from four patients and four controls.
We also observed a great variance in TCOF1 expression
among mesenchymal cells from TCS patients (n = 4) and
controls (n = 6), and the variances in these samples were
also not significantly different between the groups (p =
0.90, F test). Although the number of tested individuals
was smaller, we also detected a significantly lower expres-
sion of TCOF1 in TCS patients (~31%; Figure 2; patients
mean ± SEM = 0.9687 ± 0.1122; controls mean ± SEM =
1.414 ± 0.09010; p = 0.0213; Two-tailed unpaired t test
with Welch's correction). For this analysis, we also used as
reference a pool of RNAs.
Mutant allele detection
In order to confirm the existence of NMD mechanism, we
evaluated the expression of mutant alleles. We compared
peak heights obtained through sequencing analysis of the
nucleotides flanking the pathogenic mutation of the
gDNA versus cDNA (Figure 2). We observed the expression
of the mutant alleles in two patients (TCS16 and 23), but
in patients TCS21 and 22 we could only detect the wild-
type allele (Figure 2).
Discussion
We present here the first quantification of TCOF1 tran-
scripts in leucocytes and mesenchymal cells from TCS
patients and controls. We observed a wide range of expres-
sion levels, with a variance that was very similar for indi-
viduals with or without a pathogenic mutation in the
TCOF1  gene, and also independently from the tissue
where the mRNA was obtained. The expression levels in
leucocytes did not show dependence on age in TCS
patients.
We verified that the TCOF1 transcript levels were signifi-
cantly reduced in patients as compared to controls in all
the cell types studied. Our results demonstrated that the
dosage compensation mechanism, proposed elsewhere
[5], does not occur in adult leucocytes or mesenchymal
cells, at least at the mRNA level. However, we cannot rule
out the existence of post-translational regulatory mecha-
nisms that assure the same amounts of treacle. Alterna-
tively, the methods adopted for treacle quantification in
the previous report were not able to detect a slight reduc-
tion in protein levels [5].
Our findings are in accordance with the current hypothe-
sis of haploinsufficiency for TCS, which predicts that the
allele bearing a premature stop codon is degraded by
NMD, and consequently patients have less gene product
than normal individuals. In addition, the reduction of
TCOF1 expression (18-31%) in adult cells of TCS patients
as compared to controls is in accordance to the observed
5-25% reduction of transcript levels caused by NMD in
the presence of premature stop codon mutations in
mRNA molecules [26].
In order to confirm if NMD mechanism was associated
with the presence of null mutations in TCOF1, we evalu-
ated if the mutant allele had reduced expression in cell
culture from tissue samples of TCS patients. As we
observed complete absence of mutant alleles in individu-
als TCS21 and 22, but partial expression in TCS23 (Figure
2), we considered that NMD was present, but with varia-
Normalized TCOF1 expression levels in TCS patients (circles) and controls (squares) Figure 1
Normalized TCOF1 expression levels in TCS patients (circles) and controls (squares). A) TCOF1 expression levels 
in leucocytes samples from patients (mean ± SEM = 6.846 ± 0.3278) and controls (mean ± SEM = 8.093 ± 0.3587). B) TCOF1 
expression levels in mesenchymal cell samples from patients (mean ± SEM = 0.9687 ± 0.1122) and controls (mean ± SEM = 
1.414 ± 0.09010). Mean expression value is represented by horizontal lines.BMC Medical Genetics 2009, 10:136 http://www.biomedcentral.com/1471-2350/10/136
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ble efficiency. Interestingly, TCS16 seemed to express
both alleles in similar proportion. Although it had been
described that NMD efficiency can vary according to the
position of the premature stop codon [26], in these sam-
ples we did not observe any correlation between the loca-
tion of the mutations at N or C-terminal and absence/
reduction of mutant allele expression (Figure 2). It is pos-
sible that, in addition to NMD, other mechanisms of tran-
scriptional regulation could be resulting in this observed
differential allelic expression, such as epigenetic, environ-
mental or stochastic events [27,28].
Conclusions
We demonstrated that adult leucocytes and mesenchymal
cells from TCS patients present significantly reduced levels
of TCOF1. In addition, we showed that the mutant allele
is much less abundant than the wild type and it might be
in accordance with the hypothesis of mutant transcript
degradation through NMD. Deficiency of TCOF1 in these
cells opens a perspective to study the function of this gene
in adulthood, particularly in adult stem cells. It will be
important to verify if TCOF1 levels interfere in the renewal
capacity of stem cells during bone regeneration process, as
successful reconstruction of facial defects in TCS patients
represents a challenge to plastic surgery.
Abbreviations
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ated mRNA decay; PTC: premature termination codon;
NF: normalization factor.
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Genomic DNA (gDNA) and complementary DNA (cDNA) sequencing of mesenchymal stem cells samples from four TCS  patients Figure 2
Genomic DNA (gDNA) and complementary DNA (cDNA) sequencing of mesenchymal stem cells samples 
from four TCS patients. The pathogenic mutation of TCS patients 16, 21, 22, and 23 are c.218_222insAACC (exon 3), 
c.4344dupA (exon 24), c.431delC (exon 5), and c.4218dupG (exon 23), respectively. gDNA was sequenced with intronic prim-
ers and cDNA with exonic primers. Observing all gDNA samples, we can assume that all analyzed individuals are heterozygous 
for the pathogenic mutation. Analyzing cDNA samples, we could detect the mutant allele expression in TCS 16 and 23; TCS 21 
and 22 express only the wild-type allele. Note that even when the mutant allele is expressed (patients TCS16 and TCS23), the 
peak heights are lower.BMC Medical Genetics 2009, 10:136 http://www.biomedcentral.com/1471-2350/10/136
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Flow cytometry analysis of mesenchymal cells from patients TCS16, 
21, 22, and 23. Values represent the mean percentage of all assessed cells 
positively stained by the indicated antigens (CD31, CD73 (SH4), (SH2) 
CD105) and analyzed by flow cytometry. Graphs show relative number of 
cells (events) versus fluorescence intensity. Unmarked cells (control) were 
used as negative controls in both non-conjugated and conjugated antibod-
ies. Solid histograms (black) show marker expression; open histograms 
(grey) show no marker expression. Horizontal lines represent the range of 
positive cells interval. CD means cluster of differentiation.
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